LivaNova plc Stock
Price
Target price
€47.20
€47.20
-3.280%
-1.6
-3.280%
€57.41
14.11.25 / Stuttgart Stock Exchange
WKN: A14156 / Symbol: LIVN / Name: LivaNova / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
LivaNova plc Stock
Heavy losses for LivaNova plc today as the stock fell by -€1.600 (-3.280%).
With 17 Buy predictions and not the single Sell prediction the community is currently very high on LivaNova plc.
As a result the target price of 57 € shows a positive potential of 20.76% compared to the current price of 47.2 € for LivaNova plc.
Pros and Cons of LivaNova plc in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of LivaNova plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| LivaNova plc | -3.280% | 10.280% | 5.357% | -4.453% | 6.306% | -1.667% | 7.273% |
| Icu Medical Inc. | -1.680% | -3.279% | 18.000% | -27.607% | -19.728% | -23.871% | -28.916% |
| Bio-Rad Labs Inc. A | -0.950% | 2.083% | 2.667% | -21.680% | -14.199% | -35.925% | -47.157% |
| Neogen Corp. | -2.730% | 6.731% | 8.824% | -63.487% | -53.750% | - | - |
Comments
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Mizuho from $65.00 to $70.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Robert W. Baird from $63.00 to $70.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
LivaNova (NASDAQ:LIVN) had its price target raised by analysts at Robert W. Baird from $61.00 to $63.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
News
LivaNova to Announce Second-Quarter 2025 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE)
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than